Early research (Phase 1)Study completedNCT07069725
What this trial is testing
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Who this might be right for
Liver FibrosisHepatic Cirrhosis
AstraZeneca 8